[1]王纯,魏艳玲,黄河清,等.粪菌移植治疗帕金森病患者肠易激综合征样症状的有效性和安全性:一项单中心、自身前后对照临床研究[J].第三军医大学学报,2020,42(01):18-24.
 WANG Chun,WEI Yanling,HUANG Heqing,et al.Efficacy and safety of fecal microbiota transplantation in treatment of irritable bowel syndrome-like symptoms in Parkinson’s disease: a single-center, self-controlled clinical trial[J].J Third Mil Med Univ,2020,42(01):18-24.
点击复制

粪菌移植治疗帕金森病患者肠易激综合征样症状的有效性和安全性:一项单中心、自身前后对照临床研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第01期
页码:
18-24
栏目:
神经科学
出版日期:
2020-01-15

文章信息/Info

Title:
Efficacy and safety of fecal microbiota transplantation in treatment of irritable bowel syndrome-like symptoms in Parkinson’s disease: a single-center, self-controlled clinical trial
作者:
王纯魏艳玲黄河清陈东风
陆军军医大学(第三军医大学)大坪医院消化内科;陆军军医大学(第三军医大学)第一附属医院神经内科
Author(s):
WANG Chun WEI Yanling HUANG Heqing CHEN Dongfeng

Department of Gastroenterology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042; 2Department of Neurology, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
 

关键词:
粪菌移植帕金森病肠易激综合征肠道菌群
Keywords:
fecal bacteria transplantation Parkinson&rsquos disease irritable bowel syndrome gut microbiota
文献标志码:
A
摘要:

目的 探讨粪菌移植(fecal microbiota transplantation,FMT)治疗帕金森病患者肠易激综合征(irritable bowel syndrome,IBS)样症状的有效性和安全性。方法 选择2019年3-7月在陆军军医大学第一附属医院就诊的30例伴有便秘和/或腹泻症状的早期帕金森病(Parkinson’s disease,PD)患者,所有患者行连续3周,每周1次的FMT治疗,记录移植前后患者每周排便次数及性状、IBS相关评分量表、血常规、肝肾功指标以及相关不良反应,共随访8周。结果30例患者中便秘患者26例,与治疗前比较,第8周每周排便次数明显增加[(1.31±0.67)vs(5.27±2.75)次],Bristol大便性状量表评分明显改善[(1.77±1.03) vs (3.81±0.68)分]。腹泻患者4例,每周排便次数明显减少[(18±1.87) vs (6.75±0.43)次],Bristol大便性状量表评分明显改善[(5.75±0.43) vs (4.25±0.43)分]。至随访第8周,所有患者胃肠道症状评定量表评分明显下降[(7.7±2.72) vs (2.72±2.23)分],IBS严重程度评分明显下降[(137.83±67.86) vs (46.67±64.52)分],IBS生活质量量表评分明显下降[(21.47±14.59) vs (5.47±6.48)分],差异均有统计学意义(P<0.05)。随访期间疗效稳定,未发生严重不良反应。结论粪菌移植对改善帕金森病患者的肠易激综合征样症状安全有效。

Abstract:

Objective To evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in the treatment of irritable bowel syndrome (IBS)-like symptoms in Parkinson’s disease. MethodsA total of 30 patients with early Parkinson’s disease accompanied with constipation and/or diarrhea who were admitted to the First Affiliated Hospital from March to July 2019 were recruited in this study. All patients were given 3 consecutive weeks FMT treatment (once per week). The frequency of voluntary defecation, stool characteristics, IBS related scale scores, blood routine, liver and kidney functions, and related adverse reactions before and after FMT were detected and recorded. All of them were followed up for 8 weeks. ResultsThe 26 patients suffering from constipation had the times of defecation per week significantly increased from 1.31±0.67 times before treatment to 5.27±2.75 times in 8 week after treatment, and the score of Bristol stool trait scale improved from 1.77±1.03 to 3.81±0.68. In the 4 patients with diarrhea, the number of defecation per week was significantly reduced from 18±1.87 to 6.75±0.43 times, and the scores of Bristol stool traits scale were significantly improved from 4.25±0.43 to 5.75±0.43. Till the 8th week of follow-up, the score of gastrointestinal symptoms rating scale were significantly reduced from 7.7±2.72 to 2.72±2.23, the scores of IBS severity from 137.83±67.86 to 46.67±64.52, and the scores of IBS quality of life scale from 21.47±14.59 to 5.47±6.48 in all the patients (P<0.05). ConclusionOral FMT capsule is safe and effective in the improvement of IBS-like symptoms in Parkinson’s disease patients.

参考文献/References:

[1]KALIA L V, LANG A E. Parkinson’s disease[J]. Lancet, 2015, 386(9996): 896-912. DOI:10.1016/s0140-6736(14)61393-3.
[2]FASANO A, VISANJI N P, LIU L W, et al. Gastrointestinal dysfunction in Parkinson’s disease[J]. Lancet Neurol, 2015, 14(6): 625-639.DOI:10.1016/S1474-4422(15)00007-1.
[3]NOYCE A J, BESTWICK J P, SILVEIRA-MORIYAMA L,et al.Meta-analysis of early nonmotor features and risk factors for Parkinson disease[J]. Ann Neurol, 2012, 72(6): 893-901. DOI:10.1002/ana.23687.
[4]STIRPE P, HOFFMAN M, BADIALI D, et al. Constipation: an emerging risk factor for Parkinson’s disease?[J]. Eur J Neurol, 2016, 23(11): 1606-1613. DOI:10.1111/ene.13082.
[5]MISHIMA T, FUKAE J, FUJIOKA S, et al. The prevalence of constipation and irritable bowel syndrome in Parkinson’s disease patients according to Rome Ⅲ diagnostic criteria[J]. J Parkinsons Dis, 2017, 7(2): 353-357. DOI:10.3233/JPD-160982.
[6]MERTSALMI T H, AHO V T E, PEREIRA P A B, et al. More than constipation-bowel symptoms in Parkinson’s disease and their connection to gut microbiota[J]. Eur J Neurol, 2017, 24(11): 1375-1383. DOI:10.1111/ene.13398.
[7]LAI S W, LIAO K F, LIN C L, et al. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan[J]. Eur J Epidemiol, 2014, 29(1): 57-62. DOI:10.1007/s10654-014-9878-3.
[8]BARBARA G, FEINLE-BISSET C, GHOSHAL U C, et al. The intestinal microenvironment and functional gastrointestinal disorders[J]. Gastroenterology, 2016: S0016-S5085(16)00219-5. DOI:10.1053/j.gastro.2016.02.028.
[9]PINN D M, ARONIADIS O C, BRANDT L J. Is fecal Microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?[J]. Neurogastroenterol Motil, 2015, 27(1): 19-29. DOI:10.1111/nmo.12479.
[10]KESHAVARZIAN A, GREEN S J, ENGEN P A, et al. Colonic bacterial composition in Parkinson’s disease[J]. Mov Disord, 2015, 30(10): 1351-1360. DOI:10.1002/mds.26307.
[11]MERTSALMI T H, AHO V T E, PEREIRA P A B, et al. More than constipation-bowel symptoms in Parkinson’s disease and their connection to gut Microbiota[J]. Eur J Neurol, 2017, 24(11): 1375-1383. DOI:10.1111/ene.13398.
[12]KUROKAWA S, KISHIMOTO T, MIZUNO S, et al. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study[J]. J Affect Disord, 2018, 235: 506-512. DOI:10.1016/j.jad.2018.04.038.
[13]CAMMAROTA G, IANIRO G, TILG H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4): 569-580. DOI:10.1136/gutjnl-2016-313017.
[14]BRAAK H, DEL TREDICI K, RB U, et al. Staging of brain pathology related to sporadic Parkinson’s disease[J]. Neurobiol Aging, 2003, 24(2): 197-211. DOI:10.1016/s0197-4580(02)00065-9.
[15]KIM S, KWON S, KAM T, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease[J]. Neuron, 2019, 103(4): 627-641.e7. DOI:10.1016/j.neuron.2019.05.035.
[16]MATHEOUD D, CANNON T, VOISIN A, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1-/- mice[J]. Nature, 2019, 571(7766): 565-569. DOI:10.1038/s41586-019-1405-y.
[17]SUN M F, SHEN Y Q. Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s disease[J]. Ageing Res Rev, 2018, 45: 53-61. DOI:10.1016/j.arr.2018.04.004.
[18]SAMPSON T R, DEBELIUS J W, THRON T, et al. Gut Microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease[J]. Cell, 2016, 167(6): 1469-1480.e12. DOI:10.1016/j.cell.2016.11.018.
[19]FORSYTH C B, SHANNON K M, KORDOWER J H, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease[J]. PLoS ONE, 2011, 6(12): e28032. DOI:10.1371/journal.pone.0028032.
[20]LAI S W, LIAO K F, LIN C L, et al. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan[J]. Eur J Epidemiol, 2014, 29(1): 57-62. DOI:10.1007/s10654-014-9878-3.
[21]SUNDIN J, HMAN L, SIMRN M. Understanding the gut Microbiota in inflammatory and functional gastrointestinal diseases[J]. Psychosom Med, 2017, 79(8): 857-867. DOI:10.1097/PSY.0000000000000470.
[22]RAJILIC'-STOJANOVIC' M, JONKERS D M, SALONEN A, et al. Intestinal Microbiota and diet in IBS: causes, consequences, or epiphenomena?[J]. Am J Gastroenterol, 2015, 110(2): 278-287. DOI:10.1038/ajg.2014.427.
[23]HMAN L, TRNBLOM H, SIMRN M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(1): 36-49. DOI:10.1038/nrgastro.2014.200.
[24]HUANG H L, CHEN H T, LUO Q L, et al. Relief of irritable bowel syndrome by fecal Microbiota transplantation is associated with changes in diversity and composition of the gut Microbiota[J]. J Dig Dis, 2019, 20(8): 401-408. DOI:10.1111/1751-2980.12756.
[25]BENNET S M, OHMAN L, SIMREN M. Gut Microbiota as potential orchestrators of irritable bowel syndrome[J]. Gut Liver, 2015, 9(3): 318-331. DOI:10.5009/gnl14344.
[26]CHANG C, LIN H. Dysbiosis in gastrointestinal disorders[J]. Best Pract Res Clin Gastroenterol, 2016, 30(1): 3-15. DOI:10.1016/j.bpg.2016.02.001.
[27]HOLVOET T, JOOSSENS M, WANG J, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating[J]. Gut, 2017, 66(5): 980-982. DOI:10.1136/gutjnl-2016-312513.
[28]WICHMANN A, ALLAHYAR A, GREINER T U, et al. Microbial modulation of energy availability in the colon regulates intestinal transit[J]. Cell Host Microbe, 2013, 14(5): 582-590. DOI:10.1016/j.chom.2013.09.012.
[29]KUNKEL D, BASSERI R J, MAKHANI M D, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis[J]. Dig Dis Sci, 2011, 56(6): 1612-1618. DOI:10.1007/s10620-011-1590-5.
[30]JAHNG J, JUNG I S, CHOI E J, et al. The effects of methane and hydrogen gases produced by enteric Bacteria on ileal motility and colonic transit time[J]. Neurogastroenterol Motil, 2012, 24(2): 185-190, e92. DOI:10.1111/j.1365-2982.2011.01819.x.
[31]JALANKA-TUOVINEN J, SALOJRVI J, SALONEN A, et al. Faecal Microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome[J]. Gut, 2014, 63(11): 1737-1745. DOI:10.1136/gutjnl-2013-305994.
[32]HOLZER P, FARZI A. Neuropeptides and the microbiota-gut-brain axis[M]//Advances in experimental medicine and biology. New York: Springer, 2014: 195-219. DOI:10.1007/978-1-4939-0897-4_9.
[33]VANHOUTVIN S A, TROOST F J, KILKENS T O, et al. The effects of butyrate enemas on visceral perception in healthy volunteers[J]. Neurogastroenterol Motil, 2009, 21(9): 952-e76. DOI:10.1111/j.1365-2982.2009.01324.x.

相似文献/References:

[1]刘天蔚,谢俊霞.TH和GDNF双基因表达载体的构建及其在MES23.5细胞中的表达[J].第三军医大学学报,2008,30(01):53.
 LIU Tian-wei,XIE Jun-xia.Construction of TH-GDNF vector and its expression in a dopaminergic cell line MES23.5[J].J Third Mil Med Univ,2008,30(01):53.
[2]陈平,汪世龙,陈震,等.MnTDM阻断百草枯诱导的N27细胞生长抑制的作用[J].第三军医大学学报,2007,29(24):2343.
 CHEN Ping,WANG Shi-long,CHEN Zhen,et al.Protective effects of SOD mimetic on N27 cell injury induced by Paraquat[J].J Third Mil Med Univ,2007,29(01):2343.
[3]梁亚杰,李淑蓉,苏炳银.MPTP致小鼠黑质致密部多巴胺能神经元损伤及定量研究[J].第三军医大学学报,2006,28(05):454.
[4]赵黔鲁,柴锡庆.鱼藤酮致PC12细胞线粒体功能及超微结构的影响[J].第三军医大学学报,2005,27(07):632.
[5]郭咏萍,蒋晓江,周红杰,等.62例帕金森病伴排尿困难患者临床处理[J].第三军医大学学报,2008,30(14):1385.
 GUO Yong-ping,JIANG Xiao-jiang,ZHOU Hong-jie,et al.Management for Parkinson’s disease patients with urine voiding dysfunction: report of 62 cases[J].J Third Mil Med Univ,2008,30(01):1385.
[6]王法祥,彭国光,王加才,等.优化hα-syn基因疫苗预防注射对MPTP急性帕金森病小鼠的神经保护作用[J].第三军医大学学报,2009,31(18):1761.
 WANG Fa-xiang,PENG Guo-guang,WANG Jia-cai,et al.Preventative immunization of optimized human α-synuclein DNA vaccine protects acute mouse with MPTP-induced Parkinson’s disease[J].J Third Mil Med Univ,2009,31(01):1761.
[7]张静丽,李江超,黎冰林,等.阿尔茨海默病和帕金森病患者血清代谢组学研究[J].第三军医大学学报,2016,38(05):522.
 Zhang Jingli,Li Jiangchao,Li Binglin,et al.Serum metabolic differences between the patients with Alzheimer’s and Parkinson’s diseases[J].J Third Mil Med Univ,2016,38(01):522.
[8]荣晶晶,李七渝,谭立文,等.基于可视人的帕金森病手术靶点核团定位初步研究[J].第三军医大学学报,2012,34(06):500.
 Rong Jingjing,Li Qiyu,Tan Liwen,et al.A preliminary study on operation target localization of Parkinson’s disease based on Chinese visible human[J].J Third Mil Med Univ,2012,34(01):500.
[9]李凤,陈明,马勋泰,等.甲磺酸雷沙吉兰治疗原发性帕金森病的随机、双盲、安慰剂对照临床试验[J].第三军医大学学报,2014,36(07):696.
 Li Feng,Chen Ming,Ma Xuntai,et al.Efficacy and safety of rasagiline mesylate in treatment of idiopathic Parkinson’s disease with motor fluctuations: a randomized, double-blind, parallel-controlled, single-center trial[J].J Third Mil Med Univ,2014,36(01):696.
[10]杨辉,蔡文琴,张可成,等.胎脑黑质脑内移植后帕金森病大鼠纹状体内THmRNA含量的研究[J].第三军医大学学报,1996,18(01):0.[doi:10.16016/j.1000-5404.1996.01.008 ]
 Yang Hui,CaiWenqin,Zhang Kecheng.[J].J Third Mil Med Univ,1996,18(01):0.[doi:10.16016/j.1000-5404.1996.01.008 ]

更新日期/Last Update: 2020-01-07